ArticleJournal of asthma and allergy2026
Designing an Incremental Egg Oral Immunotherapy Protocol: A Strategic Approach with Safety as a Priority.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Egg oral immunotherapy (OIT) has demonstrated clinical efficacy; however, 10-35% of patients discontinue treatment due to severe adverse reactions, particularly during the build-up phase. To improve safety, we developed an incremental egg OIT protocol with gradual dose escalation and an extended build-up period. This study aimed to evaluate the safety and efficacy of this protocol in children with egg allergy. Patients and Methods: We retrospectively reviewed children aged 1-18 years with hen's egg allergy confirmed by oral food challenge (OFC) who initiated an incremental egg OIT protocol at Songklanagarind Hospital between August 2023 and March 2025. Demographic characteristics, serum specific immunoglobulin E (sIgE) levels to egg white, egg yolk, and ovomucoid, and adverse reactions during OIT were collected and analyzed. Results: Fourteen patients were included; four underwent egg yolk OIT (EY-OIT) and ten underwent egg white OIT (EW-OIT). The median age was 44.5 months (IQR 31-63) in the EY-OIT group and 29.5 months (IQR 22.5-65.25) in the EW-OIT group. Mild adverse reactions occurred in 6 of 14 patients (43%). Reported reactions included active eczema and itchy throat in the EY-OIT group, and perioral erythema, active eczema, and acute urticaria in the EW-OIT group. No severe adverse reactions were observed during the OIT build-up and maintenance phases. Thirteen patients (92.9%) successfully escalated doses according to the protocol, and nine patients reached the target maintenance dose. Conclusion: An incremental egg OIT protocol demonstrated a favorable safety profile in children with egg allergy. No severe adverse reactions occurred during the OIT build-up and maintenance phases, and most patients tolerated gradual dose escalation as planned, supporting the feasibility of this approach in real-world clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.